地舒单抗在骨质疏松症治疗中停药风险与应对策略的研究进展
Research advances in denosumab discontinuation and coping strategies in pharmacological therapy for osteoporosis
张博涵 1马婧2
作者信息
- 1. 解放军总医院第一医学中心骨科,北京 100853;291103 部队医院,海南三亚 572000
- 2. 解放军总医院京北医疗区,北京 100094
- 折叠
摘要
地舒单抗是一种针对性治疗骨质疏松症的新型单克隆抗体.长期使用该药物能够增加骨质疏松患者的骨密度,降低骨转换和全身多部位骨折的风险.地舒单抗抑制骨吸收的作用具有可逆性,骨质疏松患者在地舒单抗不良反应的影响下选择中断治疗后,药物的逆转效应通常导致骨转换和骨丢失的显著增加,进一步增加了停药后的骨折风险.因此,患者在停药后 1年内及时接受后续抗骨质疏松治疗很重要.本文就目前地舒单抗停药后的风险与相关危险因素、代谢机制、后续药物治疗策略的研究进展进行总结,为临床中骨质疏松患者在地舒单抗停药后接受个性化精准治疗提供参考.
Abstract
Denosumab is a novel monoclonal antibody targeted for the treatment of osteoporosis.Continued use of the drug results in sustained increases in bone mineral density,decreases in bone turnover,and reductions in the risk of systemic multiple fractures in osteoporosis patients.The anti-resorptive effect of denosumab for the bone is reversible.When the side-effects of the drug prompt the denosumab discontinuation in osteoporosis patients,the reversal is usually associated with marked increases in bone turnover and bone loss,further increasing the risk of fractures.Therefore,the patients should be given subsequent anti-osteoporosis therapy in time after stopping Denosumab during the initial year.This paper summarizes the research advances in the risks of denosumab discontinuation and related factors,metabolic mechanism,and subsequent coping strategies in pharmacological therapy for osteoporosis,so as to provide references for personalized and precise treatment on osteoporosis patients with denosumab discontinuation in clinical practice.
关键词
地舒单抗/骨质疏松症/停药/骨密度/骨折Key words
denosumab/osteoporosis/discontinuation/bone mineral density/fracture引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据